Table 2 Summary of clinical responses in 232 patients with curative objective
All, n (%) | Good, n (%) | Intermediate, n (%) | Poor, n (%) | P value | |
|---|---|---|---|---|---|
Best overall response, n (%) | |||||
CR | 116 (50.88%) | 79(70.54%) | 28(44.44%) | 9(15.79%) | < 0.0001 |
PR-negative | 69 (30.26%) | 23(20.54%) | 25(39.68%) | 21(36.84%) | |
PR-positive | 21 (9.21%) | 2(1.79%) | 7(11.11%) | 12(21.05%) | |
SD | 17 (7.46%) | 4(3.57%) | 2(3.17%) | 11(19.3%) | |
PD | 5 (2.19%) | 0 | 1(1.59%) | 4(7.02%) | |
NE | 4(1.46%) | 4(3.57%) | 0 | 0 | |
ORR | 206 (88.79) | 104 (92.86) | 60 (95.24) | 42 (73.68) | 0.0002 |
CR and PR-negative | 185 (79.74) | 102 (91.07) | 53 (84.13) | 30 (52.63) | < 0.0001 |
PFS status | |||||
No progression | 190 (81.90) | 106 (94.64%) | 56 (88.89%) | 28 (49.12%) | < 0.0001 |
Early relapse | 39 (16.81) | 6 (5.36%) | 7 (11.11%) | 26 (45.61%) | |
Late relapse* | 3 (1.29) | 0 | 0 | 3 (5.26%) | |
OS status | |||||
Alive | 209 (90.09) | 111 (99.11%) | 59 (93.65%) | 39 (68.42%) | < 0.0001 |
Death in the first 3 yrs | 21 (9.05) | 0 | 0 | 2 (3.51%) | |
Death after 3 yrs | 2 (0.86) | 1 (0.89%) | 4 (6.35%) | 16 (28.07%) | |
Follow-up (months) | |||||
Median | 41.03 | 30.03 | 49.8 | 45.03 | – |
95% CI | 32.66–49.40 | 40.02–55.89 | 50.08–74.1 | 47.93–60.09 | – |